You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 21, 2025

Nextwave Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for NEXTWAVE

NEXTWAVE has two approved drugs.

There are sixteen US patents protecting NEXTWAVE drugs.

There are thirty-four patent family members on NEXTWAVE drugs in fourteen countries.

Summary for Nextwave
International Patents:34
US Patents:16
Tradenames:2
Ingredients:1
NDAs:2

Drugs and US Patents for Nextwave

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nextwave QUILLIVANT XR methylphenidate hydrochloride FOR SUSPENSION, EXTENDED RELEASE;ORAL 202100-001 Sep 27, 2012 AB RX Yes Yes 8,062,667 ⤷  Try for Free Y ⤷  Try for Free
Nextwave QUILLIVANT XR methylphenidate hydrochloride FOR SUSPENSION, EXTENDED RELEASE;ORAL 202100-001 Sep 27, 2012 AB RX Yes Yes 8,287,903 ⤷  Try for Free Y ⤷  Try for Free
Nextwave Pharms QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No 9,545,399 ⤷  Try for Free Y ⤷  Try for Free
Nextwave Pharms QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-001 Dec 4, 2015 RX Yes No 11,633,389 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for NEXTWAVE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Oral Suspension 5 mg/mL ➤ Subscribe 2013-08-02
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: NextWave – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, understanding the competitive landscape is crucial for success. NextWave Pharmaceuticals, a specialty pharmaceutical company, has made significant strides in the industry, particularly in the field of central nervous system (CNS) disorders. This comprehensive analysis delves into NextWave's market position, strengths, and strategic insights, providing valuable information for industry professionals and investors alike.

NextWave Pharmaceuticals: A Brief Overview

NextWave Pharmaceuticals, founded in Cupertino, California, has established itself as a key player in the development of innovative CNS treatments. The company's focus on extended-release formulations for ADHD medications has set it apart in a competitive market[1].

Funding and Financial Strength

NextWave's financial journey demonstrates its ability to attract significant investment. In 2011, the company secured an impressive $45 million in Series C financing, co-led by Panorama Capital and Bay City Capital[1]. This substantial funding round underscores investor confidence in NextWave's potential and provides the company with the resources needed to advance its product pipeline and commercialization efforts.

Product Portfolio and Innovation

Quillivant XR: A Game-Changing ADHD Treatment

NextWave's flagship product, Quillivant XR, represents a significant innovation in ADHD treatment. As the first and only marketed extended-release oral liquid methylphenidate, Quillivant XR addresses a crucial need in the market[5]. This unique formulation offers several advantages:

  1. Once-daily dosing convenience
  2. Liquid form, ideal for patients who have difficulty swallowing pills
  3. Extended-release technology for consistent symptom control

QuilliChew ER: Expanding Treatment Options

Building on the success of Quillivant XR, NextWave developed QuilliChew ER, the first and only extended-release methylphenidate in a chewable tablet form[5]. This product further demonstrates NextWave's commitment to creating patient-friendly ADHD treatments.

Technological Edge: The OralXR+ Platform

NextWave's success is largely attributed to its collaboration with Tris Pharma and the use of the innovative OralXR+ platform[1]. This technology enables:

  • Sustained release in liquid, chewable, and strip forms
  • Improved patient compliance, especially for children
  • Differentiation in a crowded ADHD medication market

Strategic Partnerships and Acquisitions

Collaboration with Tris Pharma

NextWave's partnership with Tris Pharma has been instrumental in developing its innovative product line. This collaboration leverages Tris Pharma's expertise in drug delivery technologies, particularly the OralXR+ platform[1].

Acquisition by Pfizer

In a significant move that validated NextWave's market potential, Pfizer acquired the company in 2012[8]. This acquisition:

  • Provided NextWave with access to Pfizer's extensive resources and global reach
  • Demonstrated the value of NextWave's product portfolio and technology platform
  • Positioned NextWave's products for broader market penetration

Market Position and Competitive Advantage

NextWave has carved out a unique position in the ADHD treatment market. Its focus on extended-release liquid and chewable formulations addresses specific patient needs, differentiating it from competitors offering traditional pill-based medications.

"NextWave is poised for near-term success," said Gaurav Aggarwal, a partner at Panorama Capital. "In addition to NextWave's filed NDA and promising pipeline, we are excited to back such a strong executive team with a depth of industry-specific experience and record of successfully bringing products to the market. NextWave's extended-release liquid methylphenidate will compete in a multi-billion dollar market that continues to grow."[1]

Strengths and Core Competencies

1. Innovative Formulation Expertise

NextWave's ability to develop novel drug delivery systems, particularly in liquid and chewable forms, sets it apart from competitors. This expertise addresses unmet needs in the ADHD market, especially for pediatric patients.

2. Strong Intellectual Property Portfolio

The company's products are protected by patents, providing a competitive edge and market exclusivity for extended periods.

3. Strategic Partnerships

Collaborations with companies like Tris Pharma and the acquisition by Pfizer have strengthened NextWave's market position and resources.

4. Focus on High-Growth CNS Market

By concentrating on ADHD treatments, NextWave has positioned itself in a market with significant growth potential. The global ADHD therapeutics market is projected to reach $24.9 billion by 2025, with a CAGR of 6.4% from 2018 to 2025.

Challenges and Market Dynamics

1. Intense Competition

The ADHD medication market is highly competitive, with established players like Johnson & Johnson, Shire (now part of Takeda), and Eli Lilly. NextWave must continue to innovate to maintain its market share.

2. Regulatory Hurdles

As with all pharmaceutical companies, NextWave faces stringent regulatory requirements for drug approval and ongoing compliance.

3. Patent Expirations

The company must navigate the challenges of patent expirations and potential generic competition in the future.

Strategic Insights and Future Outlook

1. Expansion of Product Pipeline

To maintain growth, NextWave should continue to leverage its expertise in extended-release formulations to develop treatments for other CNS disorders.

2. Global Market Expansion

With Pfizer's backing, NextWave has the opportunity to expand its reach into international markets, particularly in Europe and Asia.

3. Digital Health Integration

Incorporating digital health technologies into ADHD management could provide NextWave with a new avenue for growth and patient engagement.

4. Focus on Patient-Centric Innovation

Continuing to develop formulations that improve patient compliance and quality of life will be crucial for NextWave's long-term success.

Industry Trends and NextWave's Position

The pharmaceutical industry is experiencing several key trends that NextWave is well-positioned to capitalize on:

  1. Personalized Medicine: NextWave's focus on patient-friendly formulations aligns with the industry's move towards more personalized treatment options.

  2. Digital Health Integration: As the industry embraces digital health solutions, NextWave could explore incorporating technology into its ADHD treatments for better patient monitoring and adherence.

  3. Focus on Rare Diseases: While ADHD is not a rare disease, NextWave's expertise in CNS disorders could be leveraged to address rarer neurological conditions.

  4. Value-Based Healthcare: NextWave's products, which offer improved compliance and potentially better outcomes, align well with the shift towards value-based care models.

Competitive Analysis: NextWave vs. Key Players

To better understand NextWave's position in the market, let's compare it to some key competitors in the ADHD treatment space:

Company Key Products Market Share Strengths
NextWave Quillivant XR, QuilliChew ER Growing Innovative formulations, Pfizer backing
Johnson & Johnson Concerta Significant Established brand, global reach
Shire (Takeda) Vyvanse, Adderall XR Market leader Diverse ADHD portfolio
Eli Lilly Strattera Moderate Non-stimulant option

The Future of NextWave in the Pharmaceutical Landscape

As we look to the future, NextWave's trajectory in the pharmaceutical landscape appears promising. The company's innovative approach to drug delivery, coupled with its focus on addressing unmet needs in the ADHD market, positions it well for continued growth and success.

Key factors that will likely shape NextWave's future include:

  1. Continued Innovation: Leveraging its expertise in extended-release formulations to develop new products and expand into other CNS disorders.

  2. Strategic Partnerships: Building on its successful collaborations to enhance its technological capabilities and market reach.

  3. Market Expansion: Utilizing Pfizer's global network to introduce its products to new markets worldwide.

  4. Patient-Centric Approach: Maintaining its focus on developing treatments that improve patient compliance and quality of life.

  5. Adapting to Industry Trends: Staying ahead of the curve in areas such as personalized medicine and digital health integration.

Key Takeaways

  • NextWave Pharmaceuticals has established a strong position in the ADHD treatment market with innovative extended-release formulations.
  • The company's key products, Quillivant XR and QuilliChew ER, address unmet needs in ADHD treatment, particularly for pediatric patients.
  • Strategic partnerships, including the acquisition by Pfizer, have significantly enhanced NextWave's market position and resources.
  • NextWave's focus on patient-friendly formulations aligns well with industry trends towards personalized medicine and value-based healthcare.
  • The company faces challenges from intense competition and potential patent expirations but is well-positioned for future growth through continued innovation and market expansion.

FAQs

  1. What makes NextWave Pharmaceuticals unique in the ADHD treatment market? NextWave stands out for its focus on developing extended-release liquid and chewable ADHD medications, addressing the needs of patients who have difficulty swallowing pills.

  2. How has the acquisition by Pfizer impacted NextWave's market position? The Pfizer acquisition has provided NextWave with access to extensive resources and global reach, potentially accelerating its product development and market expansion efforts.

  3. What are the key challenges facing NextWave in the coming years? Major challenges include intense competition in the ADHD market, navigating regulatory hurdles, and preparing for potential patent expirations.

  4. How does NextWave's product portfolio compare to those of its competitors? While competitors like Johnson & Johnson and Shire offer a wider range of ADHD treatments, NextWave's unique formulations (liquid and chewable extended-release options) provide a competitive edge in specific patient populations.

  5. What future growth opportunities exist for NextWave Pharmaceuticals? Potential growth avenues include expanding into other CNS disorders, integrating digital health technologies, and leveraging Pfizer's global network for international market expansion.

Sources cited: [1] https://www.fiercebiotech.com/biotech/nextwave-raises-45m-for-drug-launch-cns-work [5] https://www.drugpatentwatch.com/blog/the-importance-of-pharmaceutical-competitor-analysis/ [8] https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_nextwave_pharmaceuticals_inc

Last updated: 2025-02-12

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.